Study of a blood test to predict tumor response to radiation
Part of Cancer clinical trials.
This trial is testing whether a protein called CHI3L1 in your blood can help predict how well tumors will respond to radiation therapy. It is open to people with several types of cancer who are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer and are at least 18 years old.
- You have one of these cancer types: nasopharyngeal, head and neck, lung, breast, stomach, colorectal, brain (glioma), esophagus, liver, bile duct, cervix, prostate, or bladder.
- You are generally able to care for yourself and are up and about more than half of your waking hours (ECOG score 0 or 1).
- You do not have serious heart, liver, kidney, or poorly controlled diabetes or other major health problems that might get worse with treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for a new blood marker that may predict how well liver cancer will respond to radiation and what outcomes to expect. It’s for people with hepatitis B–related liver cancer who can safely receive radiation to the liver tumor.
This study looks at tumor tissue and/or blood “biomarkers” to help predict whether a solid tumor will respond well to radiation therapy. It may help doctors choose more effective treatments in the future, and it may guide your care during radiotherapy if you qualify.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study looks for “biomarkers,” or measurable signs (often from blood or samples), that may show which cancers respond better to radiation therapy. It may help doctors choose radiation treatment more precisely, especially for people who had significant side effects before.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
This study checks whether a blood test that looks for “tumor DNA” (circulating tumor DNA) can help evaluate how well neoadjuvant chemotherapy worked for breast cancer. It may help doctors better understand treatment response after surgery.
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.